Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Creative Medical Technology Holdings, Inc.CELZ · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required |
| Reliability | 0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| Peer failure rate | 0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | under $12.5M assetstotal assets $7.8M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | dilution, thin data, degenerate inputsnot computable: short runway, distress |
| Inputs computable | 6 of 14 |
| Graded from | filings received through Apr 24, 2026168 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $0.902026-10-06; market equity $5.9M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 20, 2026; the document on sec.gov.
We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following: Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 85.5 | |||||||
| Gross profitability | 0.05% | [1,5] | 32.2% | 94.3 | 372 | 2025-12-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| required facts have no common fiscal period end | |||||||
| Accruals ratio | (1.9%) | [1,6-8] | (6.6%) | 76.7 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| annual revenue must exceed $100,000 | |||||||
| Solvency, sleeve percentile 22.0 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (1.08) | [1,9-14] | (0.31) | 41.5 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| interest expense must exceed $100,000 | |||||||
| Current ratio | 25.97x | [9-10] | 2.96x | 2.5 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 81.9 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| current value must be positive and the base must exceed $100,000 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| four consecutive annual FCF observations are required; found 0 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (25.9%) | [1,8,15-16] | 2.1% | 89.5 | 704 | 2025-12-31 | |
| Net share issuance, one year | 43.0% | [3-4] | 2.5% | 74.2 | 634 | 2026-03-20 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-06 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (66.1%) | 8.0% | 8 | hotter than 8 of 100 peers |
| Distance from 52-week high | (84.6%) | (31.4%) | 6 | closer to its high than 6 of 100 peers |
| EBIT to enterprise value | (97.3%) | (1.5%) | 6 | pricier than 94 of 100 peers |
| Free cash flow yield | not computable | (1.0%) | required accounting or market input is missing | |
| Book value to price | 1.53 | 0.28 | 94 | pricier than 6 of 100 peers |
| Sales to price | 0.00 | 0.31 | 3 | pricier than 97 of 100 peers |
| Composite equity issuance, five years | not computable | 20.3% | five-year total-return history is required | |
| Relative strength against the sector, log excess return | (1.29) | (0.14) | 8 | ahead of 8 of 100 peers |
Inputs: market equity $5.7M; EBIT -$6.1M; book equity $8.7M; sales $6,000; debt $5.1M; cash $4.5M[17].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (89.9%) | ✗ fail[6,8] |
| Operating cash flow above zero | -$5.9M | ✗ fail[7] |
| Return on assets improved | (38.6 pts) | ✗ fail[6,8,15,18] |
| Operating cash flow exceeds net income | $138,563 | ✓ pass[6-7] |
| Long-term leverage fell | n/a[1,8,15] | |
| Current ratio improved | 724.7 pts | ✓ pass[9-10,19-20] |
| No new shares issued | 43.0% | ✗ fail[3-4] |
| Gross margin improved | n/a[2,5,21-22] | |
| Asset turnover improved | (0.0 pts) | ✗ fail[2,8,15,22] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a[7,23-26] |
| Months of runway | not finite |
| cash is missing at the end of the latest cash-flow quarter | |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 63 |
| 10-Q received Aug 7, 2026 | |
| Median daily dollar volume | $196,166 |
| 63 sessions | |
| Days since newest grade input | 168 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $7.8M | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:Revenues | $6,000 | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 3 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 3,696,668 | 2026-03-20 | 2026-04-24 | 10-K/A | filing · viewer · series |
| 4 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 2,585,897 | 2025-04-15 | 2025-04-25 | 10-K/A | filing · viewer · series |
| 5 | gross profit | us-gaap:GrossProfit | $3,806 | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 6 | net income | us-gaap:NetIncomeLoss | -$6.0M | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 7 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.9M | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 8 | assets | us-gaap:Assets | $6.7M | 2024-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 9 | current assets | us-gaap:AssetsCurrent | $7.4M | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 10 | current liabilities | us-gaap:LiabilitiesCurrent | $284,880 | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 11 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$70.6M | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 12 | operating income | us-gaap:OperatingIncomeLoss | -$6.1M | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 13 | book equity | us-gaap:StockholdersEquity | $7.5M | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 14 | liabilities | us-gaap:Liabilities | $284,880 | 2025-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $10.7M | 2023-12-31 | 2025-03-14 | 10-K | filing · viewer · series |
| 16 | assets | us-gaap:Assets | $19.2M | 2022-12-31 | 2024-03-22 | 10-K | filing · viewer · series |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 6,592,557 | 2026-08-07 | 2026-08-07 | 10-Q | filing · viewer · series |
| 18 | net income | us-gaap:NetIncomeLoss | -$5.5M | 2024-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 19 | current assets | us-gaap:AssetsCurrent | $6.1M | 2024-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 20 | current liabilities | us-gaap:LiabilitiesCurrent | $327,644 | 2024-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 21 | gross profit | us-gaap:GrossProfit | $6,600 | 2024-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 22 | revenue | us-gaap:Revenues | $11,000 | 2024-12-31 | 2026-03-20 | 10-K | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.8M | 2026-06-30 | 2026-08-07 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.3M | 2026-03-31 | 2026-05-08 | 10-Q | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$3.9M | 2025-09-30 | 2025-11-07 | 10-Q | filing · viewer · series |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.8M | 2025-06-30 | 2026-08-07 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.